Jemperli by GSK approved to treat endometrial cancer

Approvals

GSK has announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab) in combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H).

The company previously submitted a supplemental Biologics License Application (sBLA) supporting the new indication, which received Priority Review and was approved ahead of its Prescription Drug User Fee Act action date.

This approval means Jemperli is now indicated earlier in the treatment programme along with chemotherapy for patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.

Hesham Abdullah, senior vice president and global head of Oncology Development at GSK, commented: “Today’s expanded approval of Jemperli redefines the treatment landscape for patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer. Until now, chemotherapy alone has been the standard of care with many patients experiencing disease progression. In the RUBY trial, Jemperli plus chemotherapy demonstrated a 71% reduction in the risk of disease progression or death versus chemotherapy in this patient population, providing a statistically significant and clinically meaningful benefit. These results and today’s approval underscore our belief in the potential for Jemperli to transform cancer treatment as a backbone immuno-oncology therapy.”

Wenora Johnson, president of the board of directors of Facing Our Risk of Cancer Empowered (FORCE), added: “The endometrial cancer community is thrilled by today’s news, which changes the treatment paradigm for a population with long-term unmet needs. FORCE is grateful for the many participants and researchers who contributed to this important study. As an endometrial cancer survivor, I know how much this approval offers hope for patients with primary advanced or recurrent dMMR/MSI-H endometrial cancer.”

Contaminated cough syrup leads to WHO Medical Product Alert

The WHO has shared a medical product alert for an additional contaminated cough syrup medicine identified in Africa.

New open innovation hub opened by Astellas for tumour microenvironment research

Astellas Pharma and Mitsui Fudosan have announced that Astellas plans to establish a tumour microenvironment (TME) open innovation hub, intended to open in October 2023.

Alzheimer’s disease drug Leqembi given full approval by FDA

Japanese Eisai and US-based biotechnology company Biogen have announced that the FDA has given their Alzheimer’s disease drug Leqembi (lecanemab-irmb) full approval through the approval of a supplemental biologics license application.

First over the counter contraceptive pill approved by FDA

FDA has announced that it has approved the Opill (norgestrel) tablet for non-prescription use to prevent pregnancy.

FDA approves first cellular therapy for treatment of patients with type 1 diabetes

The FDA has announced that it has approved Lantidra, the first allogeneic (donor) pancreatic islet cellular therapy made from deceased donor pancreatic cells for the treatment of adult patients with type 1 diabetes.

Contaminated cough syrup leads to WHO Medical Product Alert

New open innovation hub opened by Astellas for tumour microenvironment research

Alzheimer’s disease drug Leqembi given full approval by FDA

First over the counter contraceptive pill approved by FDA

FDA approves first cellular therapy for treatment of patients with type 1 diabetes

Pharmafocus

Categories

Social Footprints